Ellen Kurek

News
Breast Conservation Yields Equal QOL Outcomes to Mastectomy and Reconstruction Among Patients With Breast Cancer
05/17/2022
A comparative effectiveness study showed that patients with early–stage breast cancer had similar quality of life outcomes after breast-conserving surgery with RT and after mastectomy and reconstruction without RT.
A comparative effectiveness study showed that patients with early–stage breast cancer had similar quality of life outcomes after breast-conserving surgery with RT and after mastectomy and reconstruction without RT.
A comparative effectiveness...
05/17/2022
Journal of Clinical Pathways
News
Evaluating Attrition Rates and Treatment Outcomes Among Patients With MCL
07/14/2022
Findings from a recent real-world analysis on patients with mantle cell lymphoma revealed high attrition rates, as well as a need for more effective treatment options for those in earlier lines of therapy.
Findings from a recent real-world analysis on patients with mantle cell lymphoma revealed high attrition rates, as well as a need for more effective treatment options for those in earlier lines of therapy.
Findings from a recent...
07/14/2022
Journal of Clinical Pathways
News
Systematic Review Determines the Incidence of Tumor Lysis Syndrome With Tyrosine Kinase Inhibitors in Hematologic Malignancies
06/01/2022
A recent systematic review found that the overall number of articles commenting on TLS as an adverse event is sparse and there needs to be more transparency regarding the incidence of TLS when employing newer targeted therapies.
A recent systematic review found that the overall number of articles commenting on TLS as an adverse event is sparse and there needs to be more transparency regarding the incidence of TLS when employing newer targeted therapies.
A recent systematic review found...
06/01/2022
Journal of Clinical Pathways
News
Systematic Review Protocol Explores Impact of Bortezomib in Multiple Myeloma Treatment
07/27/2022
Researchers detailed their systematic review protocol which will aim to evaluate the effects of bortezomib on the overall survival, progression-free survival, overall response rate, time to next treatment, health-related quality of life,...
Researchers detailed their systematic review protocol which will aim to evaluate the effects of bortezomib on the overall survival, progression-free survival, overall response rate, time to next treatment, health-related quality of life,...
Researchers detailed their...
07/27/2022
Journal of Clinical Pathways
News
Patients With Multiple Myeloma Incur High Health Care Costs During Follow-up
04/25/2022
A recent health care claims databases analysis revealed that among patients with MM, the mean, total, all-cause health care cost during 21 months of follow-up was found to be nearly $723,000.
A recent health care claims databases analysis revealed that among patients with MM, the mean, total, all-cause health care cost during 21 months of follow-up was found to be nearly $723,000.
A recent health care claims...
04/25/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilar Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer Treated With Chemotherapy
06/09/2022
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark...
06/09/2022
Journal of Clinical Pathways
News
Yttrium-90 Ibritumomab Tiuxetan Among Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma
05/17/2022
According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...
According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...
According to the long real-life...
05/17/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory MCL
04/27/2022
Second-generation BTKis acalabrutinib and zanubrutinib may provide additional progression-free survival among patients with relapsed or refractory mantle cell lymphoma, compared with first-generation BTKi ibrutinib, according to an early...
Second-generation BTKis acalabrutinib and zanubrutinib may provide additional progression-free survival among patients with relapsed or refractory mantle cell lymphoma, compared with first-generation BTKi ibrutinib, according to an early...
Second-generation BTKis...
04/27/2022
Journal of Clinical Pathways
News
Despite Few Genetic Services for Veterans With Cancer, Frequency of Possibly Pathogenic Germline Variants in Their Tumors Is Similar to that in the General Population
06/02/2022
Researchers at the University of Michigan applied criteria regarding gene variants that may predispose patients to cancer to determine the proportion of veterans who would benefit from genetic counseling.
Researchers at the University of Michigan applied criteria regarding gene variants that may predispose patients to cancer to determine the proportion of veterans who would benefit from genetic counseling.
Researchers at the University of...
06/02/2022
Journal of Clinical Pathways
News
Guideline Update on Use of Biomarkers for Adjuvant Endocrine and Chemotherapy in Breast Cancer
07/08/2022
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the...
07/08/2022
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use